Abstract:Natural compounds such as curcumin, a polyphenolic compound derived from the rhizome of turmeric, have gathered remarkable scientific interest due to their diverse metabolic benefits including anti-obesity potential. However, curcumin faces challenges stemming from its unfavorable pharmacokinetic profile. To address this issue, synthetic curcumin derivatives aimed at enhancing the biological efficacy of curcumin have previously been developed. In silico modelling techniques have gained significant recognition in screening synthetic compounds as drug candidates. Therefore, the primary objective of this study was to assess the pharmacokinetic and pharmacodynamic characteristics of three synthetic derivatives of curcumin. This evaluation was conducted in comparison to curcumin, with a specific emphasis on examining their impact on adipogenesis, inflammation, and lipid metabolism as potential therapeutic targets of obesity mechanisms. In this study, predictive toxicity screening confirmed the safety of curcumin, with the curcumin derivatives demonstrating a safe profile based on their LD50 values. The synthetic curcumin derivative 1A8 exhibited inactivity across all selected toxicity endpoints. Furthermore, these compounds were deemed viable candidate drugs as they adhered to Lipinski's rules and exhibited favorable metabolic profiles. Molecular docking studies revealed that both curcumin and its synthetic derivatives exhibited favorable binding scores, whilst molecular dynamic simulations showed stable binding with peroxisome proliferator-activated receptor gamma (PPARγ), csyclooxygenase-2 (COX2), and fatty acid synthase (FAS) proteins. The binding free energy calculations indicated that curcumin displayed potential as a strong regulator of PPARγ (−60.2 ± 0.4 kcal/mol) and FAS (−37.9 ± 0.3 kcal/mol), whereas 1A8 demonstrated robust binding affinity with COX2 (−64.9 ± 0.2 kcal/mol). In conclusion, the results from this study suggest that the three synthetic curcumin derivatives have similar molecular interactions to curcumin with selected biological targets. However, in vitro and in vivo experimental studies are recommended to validate these findings.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the pharmacological potential of curcumin and its synthetic derivatives in anti - obesity treatment. Specifically, the study aims to evaluate the pharmacokinetic and pharmacodynamic properties of three synthetic curcumin derivatives by computational methods and compare them with curcumin, focusing on the effects of these compounds on adipogenesis, inflammation and lipid metabolism to determine their feasibility as potential anti - obesity drugs. ### Research Background - **Obesity Problem**: Obesity has become a global public health threat, and its incidence continues to rise and is expected to reach 20% by 2025. Obesity and related metabolic complications (such as inflammation, lipotoxicity, dyslipidemia) have led to an increase in a variety of non - communicable diseases (such as diabetes, cardiovascular diseases and cancer). - **Potential of Curcumin**: Curcumin is a polyphenolic compound extracted from the rhizome of turmeric, which has significant anti - obesity potential and can play a role by regulating multiple cellular pathways such as lipid metabolism, adipogenesis and inflammation. However, the poor pharmacokinetic properties of curcumin limit its clinical application. - **Development of Synthetic Derivatives**: In order to overcome the shortcomings of curcumin, researchers have developed synthetic curcumin derivatives, aiming to improve their pharmacokinetic properties and enhance their efficacy. ### Research Objectives - **Evaluate Pharmacokinetic and Pharmacodynamic Properties**: Evaluate the pharmacokinetic and pharmacodynamic properties of curcumin and its synthetic derivatives by computational methods. - **Compare the Activity of Compounds**: Compare the activity of curcumin and its synthetic derivatives with known inhibitors, and evaluate their binding ability to proteins related to adipogenesis, inflammation and lipid metabolism. - **Predict Safety**: Evaluate the safety of compounds by predicting toxicity, hepatotoxicity and other potential adverse reactions. ### Methods - **Computational Models**: Use computational methods such as molecular docking, molecular dynamics simulation and binding free - energy calculation to evaluate the interaction between compounds and target proteins. - **Toxicity Prediction**: Use tools such as Protox II to predict the toxicity of compounds. - **Pharmacokinetic and Physicochemical Property Prediction**: Evaluate the absorption, distribution, metabolism and excretion (ADME) properties of compounds and their compliance with Lipinski's rules. ### Results - **Toxicity Assessment**: The toxicity prediction results of curcumin and synthetic derivatives show that these compounds are safe at the recommended doses. - **Pharmacokinetic and Physicochemical Properties**: All compounds comply with Lipinski's rules and have good absorption, metabolism and distribution properties. - **Molecular Docking Results**: The binding ability of curcumin and its synthetic derivatives to proteins related to adipogenesis, inflammation and lipid metabolism is better than or close to that of known inhibitors, showing good pharmacodynamic potential. ### Conclusion This study evaluated the anti - obesity potential of curcumin and its synthetic derivatives by computational methods. The results show that these compounds have similar molecular interactions and show better binding affinity in some aspects. However, further in vitro and in vivo experiments are needed to verify these findings.

A Computational Approach to Anti-Obesity Treatments